Medpace (NASDAQ:MEDP) CEO August Troendle Sells 650 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 650 shares of Medpace stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the sale, the chief executive officer directly owned 539,894 shares of the company’s stock, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Medpace Price Performance

Shares of NASDAQ:MEDP traded down $6.66 during trading on Monday, hitting $593.99. The company’s stock had a trading volume of 346,443 shares, compared to its average volume of 343,232. The company has a 50-day moving average of $565.33 and a 200-day moving average of $494.30. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The firm has a market cap of $16.58 billion, a price-to-earnings ratio of 34.82, a P/E/G ratio of 2.68 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same period in the previous year, the business earned $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Leerink Partners set a $620.00 price target on Medpace in a research report on Thursday, July 23rd. TD Cowen boosted their price objective on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Finally, Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus price target of $584.18.

Hedge Funds Weigh In On Medpace

Several institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC raised its holdings in shares of Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Medpace in the second quarter worth $296,000. Finally, M&T Bank Corp lifted its position in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after acquiring an additional 31 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.